Gil Roth10.29.13
Phase I
Boehringer tests Ablynx Nanobody in AD . . . read more
Merck presents interim NSCLC data for PD-1 inhibitor . . . read more
Phase II
Alvine begins celiac trial . . . read more
Lumena begins PBC trial . . . read more
Phase III
Charleston ends painkiller trial early . . . read more
Filings
Innovus files EjectDelay in Canada . . . read more
Pharmalink gets orphan status for Busulipo . . . read more
Boehringer tests Ablynx Nanobody in AD . . . read more
Merck presents interim NSCLC data for PD-1 inhibitor . . . read more
Phase II
Alvine begins celiac trial . . . read more
Lumena begins PBC trial . . . read more
Phase III
Charleston ends painkiller trial early . . . read more
Filings
Innovus files EjectDelay in Canada . . . read more
Pharmalink gets orphan status for Busulipo . . . read more